Navigation Links
Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
Date:2/8/2012

st and sigma-1 receptor agonist) and low dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. AVP-923 is an investigational drug and is not approved for the treatment of diabetic peripheral neuropathic pain.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

Avanir® and NUEDEXTA® are registered trademarks owned by Avanir Pharmaceuticals, Inc.

©2012 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new pro
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
2. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
3. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
4. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
6. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
7. Avanir Pharmaceuticals to Participate in Two Investor Conferences
8. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
9. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
10. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
11. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
(Date:9/2/2014)... 2, 2014  Reportlinker.com announces that a new market ... Chinese and Taiwanese Markets for Minimally Invasive Spinal ... The market for MIS spinal devices in ... is growing at a fast pace, albeit at different ... happening in China , where MIS ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the ... filed a lawsuit in Iowa ... law that restricts tools used by PBMs ... and consumers.  The law—HF 2297—forces PBMs ... use of Maximum Allowable Cost (MAC) lists that keep ...
Breaking Medicine Technology:FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
... Editor-in-Chief of New Brain Stimulation Journal, CHARLESTON, ... (MUSC) today announced the results of a functional ... Nerve Stimulation) Therapy(TM),for patients with treatment-resistant depression (TRD). ... MUSC Department of Psychiatry,appears in the August 2007 ...
Cached Medicine Technology:Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 2New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 3
(Date:9/2/2014)... 2014 Becker's Healthcare is excited ... Program on October 23-25, 2014 at the Swissotel ... - The Business and Operations of ASCs brings ... continuing education, networking events, and an exhibit hall ... Outstanding educational offerings throughout the three-day event, The ...
(Date:9/2/2014)... BOSTON (September 2, 2014 4 pm EDT): In a ... American Medical Association , a team of Boston researchers ... improve dietary quality in the United States. The researchers ... at Tufts University, Harvard University and Boston Children,s Hospital ... subsidizing healthier foods could both help people make meaningful ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Cloud Medical ... of “Cloud Based” Medical Practice Business Operations solutions and ... of Digital Cyber Security solutions for all industries announced ... on the trading floor of the CME in Chicago ... DeLaGarza stated that we are very proud of the ...
(Date:9/2/2014)... by radiation therapy survived as long as patients ... study conducted by researchers at the Stanford University ... of California. , The comprehensive analysis of nearly ... first to directly compare survival rates following the ... removal of both breasts), unilateral mastectomy (the removal ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
Breaking Medicine News(10 mins):Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 2Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 3Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
... Nov. 25 Thanksgiving meals will be delivered to approximately ... to Faith In Action/Volunteer Action for Aging, a program operated ... Plan. For more than 17 years these organizations have gathered ... in need in Long Beach, Lakewood, Signal Hill, South Bay, ...
... LOS ANGELES, Nov. 25 The Black AIDS Institute recently ... 2010. , The new Board Members are a highly diverse ... government health programs, editorial, and business entrepreneurship. The Board also ... heterosexual and gay Black men and women, some living with ...
... Broad Political Endorsements, Business, and Press Join Effort to ... again, the National Bipolar Foundation and the MedicAlert Foundation receive ... now being widely accepted as a preventive health care measure ... proclamation of endorsement via Federal Express Priority Mail from the ...
... have found evidence of a statistically significant survival ... receptor (ER)-positive tumors had high levels of phosphorylation ... a brief communication published online November 25 in ... . Approximately 50% of breast carcinomas are ...
... pressure? This simple question has been the focus of ... High Blood Pressure in Mice & Men, Does stress increase ... of intense research for many years. Now new research ... novel gene, phosducin, and the blood pressure response to stress ...
... Rituximab, already used to fight rheumatoid arthritis, could help ... (HealthDay News) -- A drug commonly used to treat ... promise in helping patients newly diagnosed with type 1 ... producing some of their own insulin, even though the ...
Cached Medicine News:Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 4Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
The Freedom Clear catheter is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for every day wear....
Freedom Clear® SS Sport Sheath is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath designed for everyday wear. Its brief sheath minimizes roll at the base of the p...
... clear, all-silicone Foley catheters eliminate patient ... Foley catheter designs. As an inert, ... creating a safe, dependable Foley catheter. ... all-silicone catheters will not leach chemicals ...
... stone manipulation and removal in ... strength permits the basket to ... than standard flat-wire designs. The ... one-handed operation. Supplied sterile in ...
Medicine Products: